These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 24028858)
1. Reduced breast cancer incidence in women treated with subcutaneous testosterone, or testosterone with anastrozole: a prospective, observational study. Glaser RL; Dimitrakakis C Maturitas; 2013 Dec; 76(4):342-9. PubMed ID: 24028858 [TBL] [Abstract][Full Text] [Related]
2. Incidence of invasive breast cancer in women treated with testosterone implants: a prospective 10-year cohort study. Glaser RL; York AE; Dimitrakakis C BMC Cancer; 2019 Dec; 19(1):1271. PubMed ID: 31888528 [TBL] [Abstract][Full Text] [Related]
3. Testosterone and breast cancer prevention. Glaser R; Dimitrakakis C Maturitas; 2015 Nov; 82(3):291-5. PubMed ID: 26160683 [TBL] [Abstract][Full Text] [Related]
4. Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women. Tamimi RM; Hankinson SE; Chen WY; Rosner B; Colditz GA Arch Intern Med; 2006 Jul; 166(14):1483-9. PubMed ID: 16864758 [TBL] [Abstract][Full Text] [Related]
5. Reduction in proliferation with six months of letrozole in women on hormone replacement therapy. Fabian CJ; Kimler BF; Zalles CM; Khan QJ; Mayo MS; Phillips TA; Simonsen M; Metheny T; Petroff BK Breast Cancer Res Treat; 2007 Nov; 106(1):75-84. PubMed ID: 17221152 [TBL] [Abstract][Full Text] [Related]
6. Role of anastrozole across the breast cancer continuum: from advanced to early disease and prevention. Nabholtz JM Oncology; 2006; 70(1):1-12. PubMed ID: 16439860 [TBL] [Abstract][Full Text] [Related]
7. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. Confavreux CB; Fontana A; Guastalla JP; Munoz F; Brun J; Delmas PD Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847 [TBL] [Abstract][Full Text] [Related]
8. Breast cancer incidence in postmenopausal women using testosterone in addition to usual hormone therapy. Dimitrakakis C; Jones RA; Liu A; Bondy CA Menopause; 2004; 11(5):531-5. PubMed ID: 15356405 [TBL] [Abstract][Full Text] [Related]
9. Focus on anastrozole and breast cancer. Mokbel K Curr Med Res Opin; 2003; 19(8):683-8. PubMed ID: 14687437 [TBL] [Abstract][Full Text] [Related]
10. Effect of baseline oestradiol serum concentration on the efficacy of anastrozole for preventing breast cancer in postmenopausal women at high risk: a case-control study of the IBIS-II prevention trial. Cuzick J; Chu K; Keevil B; Brentnall AR; Howell A; Zdenkowski N; Bonanni B; Loibl S; Holli K; Evans DG; Cummings S; Dowsett M Lancet Oncol; 2024 Jan; 25(1):108-116. PubMed ID: 38070530 [TBL] [Abstract][Full Text] [Related]
12. Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: a phase II Trial of the Sarah Cannon Oncology Research Consortium. Yardley DA; Burris HA; Clark BL; Shipley D; Rubin M; Barton J; Arrowsmith E; Hainsworth JD Clin Breast Cancer; 2011 Jun; 11(3):146-52. PubMed ID: 21665134 [TBL] [Abstract][Full Text] [Related]
13. Short-term biomarker modulation prevention study of anastrozole in women at increased risk for second primary breast cancer. Arun B; Valero V; Liu D; Brewster A; Green M; Gutierrez-Barrera A; Akar U; Rivera E; Esteva FJ; Buzdar AU; Hortobagyi GN; Sneige N Cancer Prev Res (Phila); 2012 Feb; 5(2):276-82. PubMed ID: 22102688 [TBL] [Abstract][Full Text] [Related]
14. A prospective, multicenter, controlled, observational study to evaluate the efficacy of a patient support program in improving patients' persistence to adjuvant aromatase inhibitor medication for postmenopausal, early stage breast cancer. Yu KD; Zhou Y; Liu GY; Li B; He PQ; Zhang HW; Lou LH; Wang XJ; Wang S; Tang JH; Liu YH; Wang X; Jiang ZF; Ma LW; Gu L; Cao MZ; Zhang QY; Wang SM; Su FX; Zheng H; Li HY; Tang LL; Sun SR; Liu JP; Shao ZM; Shen ZZ Breast Cancer Res Treat; 2012 Jul; 134(1):307-13. PubMed ID: 22527106 [TBL] [Abstract][Full Text] [Related]
15. Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group. Dubsky PC; Jakesz R; Mlineritsch B; Pöstlberger S; Samonigg H; Kwasny W; Tausch C; Stöger H; Haider K; Fitzal F; Singer CF; Stierer M; Sevelda P; Luschin-Ebengreuth G; Taucher S; Rudas M; Bartsch R; Steger GG; Greil R; Filipcic L; Gnant M J Clin Oncol; 2012 Mar; 30(7):722-8. PubMed ID: 22271481 [TBL] [Abstract][Full Text] [Related]
16. The breast cancer "plunge" after initial publication of the WHI results: an alternative explanation. Simon JA; Nahum GG; Stanislaw H; Gaines T Maturitas; 2010 Jul; 66(3):277-84. PubMed ID: 20471761 [TBL] [Abstract][Full Text] [Related]
17. Breast Cancer Incidence Reduction in Women Treated with Subcutaneous Testosterone: Testosterone Therapy and Breast Cancer Incidence Study. Donovitz G; Cotten M Eur J Breast Health; 2021 Apr; 17(2):150-156. PubMed ID: 33870115 [TBL] [Abstract][Full Text] [Related]
18. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. ; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061 [TBL] [Abstract][Full Text] [Related]
19. Experience of hormonal therapy with anastrozole for previously treated metastatic breast cancer. Lavrenkov K; Man S; Geffen DB; Cohen Y Isr Med Assoc J; 2002 Mar; 4(3):176-7. PubMed ID: 11908256 [TBL] [Abstract][Full Text] [Related]
20. Anastrozole ('Arimidex') blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer. Miller WR; Stuart M; Sahmoud T; Dixon JM Br J Cancer; 2002 Oct; 87(9):950-5. PubMed ID: 12434282 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]